Skip to main content
. 2021 Dec 19;21:686. doi: 10.1186/s12935-021-02404-x

Table 1.

Characteristics of the included studies

Study Year Region Tumor type Sample size (low/high) HR (95% CI) Outcome Method Follow-up months NOS
Li [18] 2020 China NSCLC 63 (31/32) 0.44 (0.23, 0.84) OS qRT-PCR 60 7
Yang [13] 2019 China CRC 135 (43/92) 0.36 (0.16, 0.81) CP, OS qRT-PCR 60 7
Zhao [26] 2019 China OSCC 73 (37/36) 0.63 (0.35, 1.13) CP, OS qRT-PCR 60 7
Hao [19] 2020 China ccRCC 66 (33/33) 0.55 (0.28, 1.08) CP, OS qRT-PCR 60 7
Liang [17] 2021 China GC 36 (18/18) 0.47 (0.24, 0.92) OS qRT-PCR 60 6
Qin [16] 2021 China GC 98 (49/49) 0.36 (0.13, 1.00) CP, OS qRT-PCR 36 6
Zhang [27] 2020 China ccRCC 76 (38/38) 0.33 (0.09, 1.19) OS qRT-PCR 60 7
Tu [20] 2021 China OSC 40 (21/19) 0.33 (0.09, 1.21) OS qRT-PCR 60 6
Wei [15] 2019 China SKCM 54 (27/27) 2.97 (1.64, 5.36) CP, OS qRT-PCR 105 7

NSCLC non-small cell lung cancer, CRC colorectal cancer, OSCC Oral squamous cell carcinoma, ccRCC clear cell renal cell carcinoma, GC gastric cancer, SKCM skin cutaneous melanoma, OSC osteosarcoma, CP clinicopathological parameters, OS overall survival, HR hazard ratios, CI confidence intervals, NA not available, NOS Newcastle–Ottawa Scale